Aquestive Therapeutics Inc (NAS:AQST)
$ 3.235 -0.035 (-1.07%) Market Cap: 294.51 Mil Enterprise Value: 236.98 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 55/100

Aquestive Therapeutics Inc at JMP Securities Life Sciences Conference Transcript

May 15, 2023 / 04:00PM GMT
Release Date Price: $2.15 (+9.14%)
Jason Butler
JMP Securities - Analyst

Good afternoon, everybody. Thank you again for joining us at the JMP Securities Life Science Conference. I'm Jason Butler, a member of the research team here at JMP. Excited to be joined next by Aquestive Therapeutics.

Aquestive is a company that has a pipeline of approved and development-stage candidates that are leveraging a core film technology, which we'll get into. An exciting year behind and ahead of us. Lead program AQST-109 for development of treatment of anaphylaxis. It's a sublingual oral form of epinephrine. And beyond that, there are, again, a broad pipeline, which we'll talk about.

Happy to be joined by Dan Barber, company CEO; and several members of the senior management team, which, Dan, I'll let you introduce. But Dan, thank you for being with us.

Dan Barber
Aquestive Therapeutics, Inc. - CEO, President, & Director

Thanks for having us, Jason. We appreciate it. We appreciate JMP hosting this event. And yes, I did bring a small army with me today, so I apologize for that.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot